Tab. 5.

The influence of compounds 3.14, 3.16 and 3.18 on the growth of individual tumor cell lines (log GI50 ≤ −5.65)

Cpd.	Cancer	Cell line	log GI50	log TGI	Log LC50
3.14	Leukemia	RPMI-8226	−5.70	> −4.00	> −4.00
		SR	−5.83	> −4.00	> −4.00
	NSC lung cancer	A549/ATCC	−5.66	> −4.00	> −4.00
	Colon cancer	HCT-116	−5.66	−4.97	> −4.00
		HT29	−5.74	> −4.00	> −4.00
	CNS cancer	SF-539	−5.80	−5.50	−5.21
		SNB-75	−6.07	−4.90	−4.36
	Melanoma	LOX IMVI	−5.88	−5.53	−5.18
	Renal cancer	A498	−5.88	−4.51	> −4.00
		ACHN	−5.88	−5.46	−5.46
		CAKI-1	−5.94	> −4.00	> −4.00
		UO-31	−5.79	−4.61	> −4.00
3.16	Colon cancer	COLO 205	−5.76	−5.37	−4.93
		HT29	−5.66	−4.91	> −4.00
	CNS cancer	SF-539	−5.67	−5.22	−4.62
		SNB-75	−5.72	−4.87	−4.43
	Melanoma	LOX IMVI	−5.76	−5.44	−5.11
		SK-MEL-5	−5.66	−5.23	−4.67
		UACC-257	−5.68	−5.29	−4.77
	Renal cancer	A498	−6.29	−5.21	−4.51
		ACHN	−5.68	−4.93	−4.33
		CAKI-1	−5.66	−4.98	−4.07
		UO-31	−5.79	−5.07	−4.43
3.18	Leukemia	RPMI-8226	−5.71	−5.31	−4.51
	NSC lung cancer	A549/ATCC	−5.77	−5.48	−5.20
		HOP-92	−6.20	−5.14	−4.47
		NCI-H460	−5.80	−5.49	−5.19
		NCI-H522	−5.80	−5.49	−5.18
	Colon cancer	COLO 205	−5.88	−5.54	−5.20
		HCT-116	−5.93	−5.42	−4.79
		HT29	−5.96	−5.50	−5.03
		SW-620	−5.65	−4.96	−4.43
	CNS cancer	SF-539	−5.79	−5.45	−5.10
		SNB-75	−5.81	−5.33	−4.70
		U251	−5.78	−5.46	−5.15
	Melanoma	LOX IMVI	−5.89	−5.28	−4.61
		MALME-3M	−5.68	−5.29	−4.65
		SK-MEL-5	−5.74	−5.34	−4.86
		UACC-257	−5.79	−5.51	−5.24
		UACC-62	−5.79	−5.38	−4.79
	Ovarian cancer	OVCAR-3	−5.78	−5.46	−5.15
		OVCAR-4	−5.75	−5.33	−4.82
		OVCAR-8	−5.84	−5.46	−5.08
	Renal cancer	786-0	−5.73	−5.33	−4.84
		ACHN	−5.81	−5.20	−4.45
		RXF 393	−5.75	−5.34	−4.74
	Prostate cancer	PC-3	−5.70	−5.01	−4.47
	Breast cancer	MCF7	−5.81	−5.39	−4.90
		MDA-MB-231/ATCC	−5.76	−5.17	−4.48
		MDA-MB-468	−5.75	−5.37	−4.98